Skip to content
DraconiticResearch
Search Sources API
197,688 studies31 sourcesUpdated 27 min ago
Peer-reviewedCC BY-NCBleeding, Thrombosis and Vascular Biology

PO025 | CHARACTERIZATION OF PLATELET DYSFUNCTION IN NOONAN SYNDROME PATIENTS

Abstract

Background and aims. Noonan syndrome (NS) is a RASopathy characterized by dysregulation of the Ras/MAPK pathway and frequently associated with bleeding diathesis. Although hemostatic abnormalities are reported in the majority of patients, the underlying mechanisms remain incompletely defined, particularly with regard to platelet function. Preliminary evidence suggests a high prevalence of platelet defects, but their functional characterization and pathway involvement are still poorly delineated. This study aimed to refine the platelet dysfunction phenotype in NS by integrating aggregation and secretion data. Methods. In this case–control monocentric study, 29 NS patients were compared with 20 age-matched healthy controls at a single center. Bleeding tendency was assessed using the ISTH-BAT score. Standard coagulation parameters (PT, aPTT, fibrinogen, platelet count) were evaluated. Platelet function was investigated by light transmission aggregometry (LTA) using adenosine diphosphate (ADP), collagen, epinephrine, arachidonic acid (AA), and PAR1-activating peptide (PAR1-AP). Maximal aggregation (MA, %) and collagen lag phase (LP, sec) were recorded. Platelet secretion was assessed by flow cytometry through CD63 and CD62p expression after stimulation. Platelet Function Analyzer (PFA-100) closure times were available in a subset of patients. Results. An abnormal ISTH-BAT score (>3) was observed in 24% of NS patients. PT, fibrinogen levels, and platelet count were comparable between groups, whereas prolonged aPTT was detected in 30% of patients. LTA revealed a consistent and pathway-specific impairment of platelet aggregation. ADP-induced responses were markedly reduced, with MA <60% in 91.6% and 79% of patients at 2 μM and 4 μM, respectively. Collagen-induced aggregation was also impaired, with MA <75% in 42% and prolonged LP (>50 sec) in 87% of patients. Impaired responses were also observed with epinephrine (MA <60% at 180 sec in 87% NS) and PAR1-AP (MA <75% in 45.8% NS). In contrast, AA-induced aggregation was largely preserved, suggesting selective pathway involvement rather than a global defect. Flow cytometry confirmed a secretion defect, with reduced CD63 and CD62p expression after PAR1-AP stimulation. Prolonged PFA-CEPI and PFA-ADP closure times were observed in 82% and 47% of tested patients, respectively. Conclusions. This study demonstrates that the majority of patients with NS exhibit platelet dysfunction, characterized by impaired aggregation responses to ADP, collagen, and thrombin receptor stimulation, and associated with defective granule secretion. Platelet dysfunction may be detected by prolonged PFA-CEPI closure time. These findings underscore the importance of identifying and characterizing platelet abnormalities in NS patients to optimize the management of bleeding symptoms and to guide hemostatic support during surgical or invasive procedures.

Related

  1. The Diverse Clinical Spectrum of Noonan Syndrome in Pediatric Endocrinology: From Classical to Atypical Phenotypes
    Sara Aszkiełowicz, Anna Łupińska, Arkadiusz Zygmunt +1
    Journal of clinical medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Real-world patterns of growth hormone treatment in Japanese children with short stature associated with small for gestational age, Turner syndrome, Noonan syndrome, achondroplasia, and hypochondroplasia: a retrospective database study
    Jun Mori, Akie Nakamura, Masanobu Kawai +4
    Endocrine JournalPeer-reviewedCC BY-NC-NDFull textEndocrinology & metabolismJ-STAGE
  3. Beyond the usual: coronary artery abnormalities in Noonan syndrome
    Bilgehan Betül Biçer, Hayrettin Hakan Aykan, Ercan Tutar
    The Turkish Journal of PediatricsPeer-reviewedCC BYFull textObstetrics, gynaecology & paediatricsDOAJ
  4. Efficacy of autologous adipose-derived stromal vascular fraction and platelet-rich plasma intracavernous injections in patients with erectile dysfunction: a retrospective comparative study
    Ahmet Tevfik Albayrak, Yasar Basaga, Mehmet Comert +4
    BMC UrologyPeer-reviewedCC BYFull textPsychiatry & mental healthDOAJ
  5. Development and Population-Based Prognostic Utility Assessment of an ICD-10-CM-Based Prediction Model to Identify Left Ventricular Systolic Dysfunction: Discrimination Performance and Population-Based Evaluation in 83,357 Patients with Acute Coronary Syndrome
    Andreea Eunice Cosa, Marc Llagostera Martin, Sílvia Jovells-Vaqué +13
    Journal of cardiovascular development and diseasePeer-reviewedCC BYFull textCardiovascular medicineEurope PMC
BibTeX
@article{sorrentino2026po025,
  title = {{PO025 | CHARACTERIZATION OF PLATELET DYSFUNCTION IN NOONAN SYNDROME PATIENTS}},
  author = {Silvia Sorrentino},
  journal = {Bleeding, Thrombosis and Vascular Biology},
  year = {2026},
  month = oct,
  url = {https://www.btvb.org/btvb/article/view/841},
  note = {CC BY-NC},
}
RIS
TY  - JOUR
TI  - PO025 | CHARACTERIZATION OF PLATELET DYSFUNCTION IN NOONAN SYNDROME PATIENTS
AU  - Silvia Sorrentino
PY  - 2026
DA  - 2026/10/26
JO  - Bleeding, Thrombosis and Vascular Biology
UR  - https://www.btvb.org/btvb/article/view/841
AB  - Background and aims. Noonan syndrome (NS) is a RASopathy characterized by dysregulation of the Ras/MAPK pathway and frequently associated with bleeding diathesis. Although hemostatic abnormalities are reported in the majority of patients, the underlying mechanisms remain incompletely defined, particularly with regard to platelet function. Preliminary evidence suggests a high prevalence of platelet defects, but their functional characterization and pathway involvement are still poorly delineated. This study aimed to refine the platelet dysfunction phenotype in NS by integrating aggregation and secretion data. Methods. In this case–control monocentric study, 29 NS patients were compared with 20 age-matched healthy controls at a single center. Bleeding tendency was assessed using the ISTH-BAT score. Standard coagulation parameters (PT, aPTT, fibrinogen, platelet count) were evaluated. Platelet function was investigated by light transmission aggregometry (LTA) using adenosine diphosphate (ADP), collagen, epinephrine, arachidonic acid (AA), and PAR1-activating peptide (PAR1-AP). Maximal aggregation (MA, %) and collagen lag phase (LP, sec) were recorded. Platelet secretion was assessed by flow cytometry through CD63 and CD62p expression after stimulation. Platelet Function Analyzer (PFA-100) closure times were available in a subset of patients. Results. An abnormal ISTH-BAT score (>3) was observed in 24% of NS patients. PT, fibrinogen levels, and platelet count were comparable between groups, whereas prolonged aPTT was detected in 30% of patients. LTA revealed a consistent and pathway-specific impairment of platelet aggregation. ADP-induced responses were markedly reduced, with MA <60% in 91.6% and 79% of patients at 2 μM and 4 μM, respectively. Collagen-induced aggregation was also impaired, with MA <75% in 42% and prolonged LP (>50 sec) in 87% of patients. Impaired responses were also observed with epinephrine (MA <60% at 180 sec in 87% NS) and PAR1-AP (MA <75% in 45.8% NS). In contrast, AA-induced aggregation was largely preserved, suggesting selective pathway involvement rather than a global defect. Flow cytometry confirmed a secretion defect, with reduced CD63 and CD62p expression after PAR1-AP stimulation. Prolonged PFA-CEPI and PFA-ADP closure times were observed in 82% and 47% of tested patients, respectively. Conclusions. This study demonstrates that the majority of patients with NS exhibit platelet dysfunction, characterized by impaired aggregation responses to ADP, collagen, and thrombin receptor stimulation, and associated with defective granule secretion. Platelet dysfunction may be detected by prolonged PFA-CEPI closure time. These findings underscore the importance of identifying and characterizing platelet abnormalities in NS patients to optimize the management of bleeding symptoms and to guide hemostatic support during surgical or invasive procedures.
SN  - 2785-5309
ER  -